IgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer

Abstract

Recent studies suggest that B cells could play an important role in the tumor microenvironment. However, the role of humoral responses in endometrial cancer remains insufficiently investigated. Using a cohort of 107 patients with different histological subtypes of endometrial carcinoma, we evaluated the role of coordinated humoral and cellular adaptive immune responses in endometrial cancer. Concomitant accumulation of T, B, and plasma cells at tumor beds predicted better survival. However, only B-cell markers corresponded with prolonged survival specifically in high-grade endometrioid type and serous tumors. Immune protection was associated with class-switched IgA and, to a lesser extent, IgG. Expressions of polymeric immunoglobulin receptor (pIgR) by tumor cells and its occupancy by IgA were superior predictors of outcome and correlated with defects in methyl-directed DNA mismatch repair. Mechanistically, pIgR-dependent, antigen-independent IgA occupancy drove activation of inflammatory pathways associated with IFN and TNF signaling in tumor cells, along with apoptotic and endoplasmic reticulum stress pathways, while thwarting DNA repair mechanisms. Together, these findings suggest that coordinated humoral and cellular immune responses, characterized by IgA:pIgR interactions in tumor cells, determine the progression of human endometrial cancer as well as the potential for effective immunotherapies.

Significance:

This study provides new insights into the crucial role of humoral immunity in human endometrial cancer, providing a rationale for designing novel immunotherapies against this prevalent malignancy.

See related commentary by Osorio and Zamarin, p. 766

Funding

NCI NIH HHS

R01 CA233512

NCI NIH HHS

U01 CA232758

NIGMS NIH HHS

P30 GM114732

NCI NIH HHS

R01 CA211913

NCI NIH HHS

P30 CA076292

NCI NIH HHS

U01 CA232382

NCI NIH HHS

R01 CA240434

NCI NIH HHS

R01 CA157664

NCI NIH HHS

R01 CA262121

NCI NIH HHS

R01 CA178687

NCI NIH HHS

U54 CA193489

NCI NIH HHS

T32 CA009140

NCI NIH HHS

P01 CA250984

NCI NIH HHS

R01 CA124515

NCI NIH HHS

R01 CA184185

CCSG

CA076292

CCSG

R01CA157664

CCSG

R01CA124515

CCSG

R01CA178687

CCSG

R01CA211913

CCSG

R01CA184185

CCSG

T32CA009140

National Cancer Institute

U01CA232382

National Cancer Institute

U54CA193489